Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAOK1 | Q7L7X3 | 6/20 | 0.68 |
| ▸ | TAOK3 | Q9H2K8 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652164 | 0.87 | TAOK3 (0.66) | TAOK1TAOK3LMNAALDH1A1HPGD | |
| SCHEMBL5652653 | 0.87 | TAOK1 (0.66) | TAOK1TAOK3LMNAALDH1A1HPGD | |
| SCHEMBL5654657 | 0.86 | TAOK1 (0.67) | TAOK1TAOK3LMNAALDH1A1HPGD | |
| SCHEMBL5653045 | 0.83 | TAOK1 (0.68) | TAOK1TAOK3LMNAALDH1A1HPGD | |
| SCHEMBL5652352 | 0.83 | TAOK1 (0.62) | TAOK1TAOK3LMNAALDH1A1HPGD | |
| SCHEMBL31730316 | 0.81 | TAOK1 (1.00) | TAOK1TAOK3LMNAALDH1A1HPGD | |
| SCHEMBL29131611 | 0.73 | HTT (0.60) | TAOK1TAOK3ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL29131608 | 0.73 | HTT (0.60) | TAOK1TAOK3ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL29131618 | 0.72 | KMT2A (0.56) | ALDH1A1L3MBTL1KMT2AMEN1HTT | |
| SCHEMBL29131615 | 0.72 | KMT2A (0.56) | ALDH1A1L3MBTL1KMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | claimed |
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | TAOK1, TAOK3, MAP3K6 | TAOK1 1/4885TAOK3 2/4885LMNA 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.